Mesothelioma, a rare and aggressive cancer mainly caused by asbestos exposure, mostly affects the lining of the lungs, but can also affect the lining of the abdomen, heart, and testicles. Older adults are mostly at risk, especially those who worked with asbestos. A new article from the Australasian Journal on[…]
Pleural Mesothelioma
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Primary Outcome Measures Number of Patients who Experience Dose-Limiting Toxicity Number of patients who experience a treatment-related adverse event Objective response rate (ORR) Duration of response (DOR) Progression free survival (PFS) Overall survival (OS) Secondary Outcome Measures Area under the plasma concentration versus time curve (AUC) Time to achieve maximal[…]
Immunotherapy to Treat Pleural Mesothelioma
Malignant pleural mesothelioma is a rare and very aggressive cancer with a poor outlook. One cancer treatment has brought hope though. The treatment is known as immune checkpoint inhibitors. There is potential for better outcomes when patients are given this treatment. A new article in Open Respiratory Archives provides a[…]
Hemithoracic Arc Radiotherapy Post Pleural Decortication
Primary Outcome Measures Acute Radiation Toxicity late radiation toxicity Inclusion Criteria Evidence of metastatic disease. Underwent Pleural decortication. Able to provide informed consent. Exclusion Criteria Poor pulmonary function tests. Recurrent or palliative cases. Inability to attend full course of Radiotherapy or follow up visits.
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma (FAPI-PM)
Primary Outcome Measures Diagnostic Performance Secondary Outcome Measures Location biopsy Staging Patient Management Uptake Values Changes uptake parameters due to anticancer treatment Correlate immunohistochemistry Incidental findings Safety Evaluation FAPI-injection Overall survival Recurrence/Progression Free Survival Response evaluation Interobserver reliability Inclusion Criteria Patients with pleural lesions suspicious of pleural mesothelioma and referred[…]
CAR-T Cell Therapy for Mesothelioma
Mesothelioma is a rare and aggressive cancer mainly caused by asbestos exposure. With the disease being rare, there are limited treatment options for the disease. This is especially true for elderly patients. They can struggle with conventional therapies due to their age and health problems. One therapy known as Chimeric[…]
Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE VariaTionS (MAGNETS)
Primary Outcome Measures the comparison of prevalence of germline mutations in MPM patients vs asbestos exposed healthy subjects Secondary Outcome Measures Secondary aim will be the comparison of overall survival (OS) according to mutational status in MPM patients. Inclusion Criteria Inclusion Criteria Cohort A: Patient with a documented diagnosis of[…]
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Primary Outcome Measures Establish the recommended phase 2 dose (RP2D) of TNhYP218 CAR T cells based on dose-limiting toxicity (DLT) of defined adverse events (AEs). Determine the preliminary objective response rate of TNhYP218 CAR T cells in a limited number of participants with mesothelioma treated at the recommended phase 2[…]
Surgeries for Mesothelioma
Pleural mesothelioma is a very rare and aggressive cancer mainly caused by asbestos exposure. The survival time is very low, with people typically surviving around 9 to 20 months after treatment starts. The overall survival rate is around five percent, which means only five percent of people still live after[…]
Blood Biomarkers for Mesothelioma
A mesothelioma diagnosis is hard to receive and can be very overwhelming. Different research outcomes can help doctors and patients make better decisions though. One area of research is blood-based biomarkers. Two biomarkers that can help monitor mesothelioma include mesothelin-related protein (SMRP) and cancer antigen 125 (CA-125). They help monitor[…]